CLINICAL STUDIES
Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty
Results of the glycoprotein receptor antagonist patency evaluation (GRAPE) pilot study
Lambert F. M. van den Merkhof, MD*,
Felix Zijlstra, MD, PhD ,
Hans Olsson, MD ,
Lars Grip, MD, PhD ,
Gerrit Veen, MD, PhD||,
Frits W. H. M. Bär, MD, PhD¶,
Marcel J. B. M. van den Brand, MD, PhD#,
Maarten L. Simoons, MD, PhD, FACC# and
Freek W. A. Verheugt, MD, PhD, FACC*
* Heartcenter, University Hospital, Nijmegen, The Netherlands
Weezenlanden Hospital, Zwolle, The Netherlands
Örebro Medical Center Hospital, Örebro, Sweden
Sahlgrenska University Hospital, Göteborg, Sweden
|| Free University Hospital, Amsterdam, The Netherlands
¶ University Hospital Maastricht, Maastricht, The Netherlands
# Thoraxcenter, University Hospital, Rotterdam, The Netherlands
Manuscript received August 24, 1998;
revised manuscript received December 1, 1998,
accepted January 14, 1999.
Reprint requests and correspondence: Dr. Freek W.A. Verheugt, Department of Cardiology, Heartcenter, University Hospital, P.O. Box 9101, Nijmegen, 6500 HB The Netherlands.
f.verheugt{at}cardio.azn.nl
OBJECTIVES
We sought to study the effect of early infusion of abciximab on coronary patency before primary angioplasty in patients with acute myocardial infarction.
BACKGROUND
Glycoprotein IIb/IIIa antagonists have proved to be effective in reducing ischemic events associated with coronary angioplasty. The present study explores whether abciximab alone, without administration of thrombolytic therapy, may induce reperfusion in patients with acute myocardial infarction.
METHODS
In the Glycoprotein Receptor Antagonist Patency Evaluation pilot study 60 patients with less than 6 h signs and symptoms of acute myocardial infarction eligible for primary angioplasty received in the emergency room a bolus of abciximab 250 µg/kg followed by a 12-h infusion of 10 µg/min. All patients were also treated with an oral dose of 160 mg aspirin and 5,000 IU of heparin intravenously. As soon as possible a diagnostic angiography was performed to evaluate the patency of the infarct-related artery.
RESULTS
The median time between onset of symptoms and the administration of the abciximab bolus was 150 min (range 45 to 345), and the median time between abciximab bolus and first contrast injection in the infarct-related artery was 45 min (range 10 to 150). In 24 patients (40%, 95% confidence interval 28% to 52%) Thrombolysis in Myocardial Infarction (TIMI) flow grade 2 or 3 was observed at a median time of 45 min (range 10 to 150) after abciximab bolus; TIMI flow grade 3 was observed in 11 patients (18%, 95% confidence interval 9% to 28%). There was no difference in percentage of TIMI flow grade 2 or 3 between patients who received abciximab within 2.5 h after onset of symptoms or thereafter.
CONCLUSIONS
Abciximab therapy given in the emergency room in patients awaiting primary angioplasty is associated with full reperfusion (TIMI flow grade 3) in about 20% and with TIMI flow grade 2 or 3 in about 40% of the patients at a median time of 45 min. These figures are higher than those in primary angioplasty trials without such pretreatment. Randomized controlled trials of very early infusion of abciximab, either prehospital or in-hospital, in patients eligible for angioplasty are warranted.
|
Abbreviations and Acronyms
| | GRAPE | = Glycoprotein Receptor Antagonist Patency Evaluation | | GUSTO | = Global Utilization of Streptokinase and Tissue Plasminogen Activator in Occluded Arteries | | TIMI | = Thrombolysis in Myocardial Infarction |
|
This article has been cited by other articles:
|
|
|
|
 
P. Ortolani, A. Marzocchi, C. Marrozzini, T. Palmerini, F. Saia, N. Taglieri, F. Baldazzi, G. Dall'Ara, P. Nardini, S. Gianstefani, et al.
Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network
Eur. Heart J.,
November 7, 2008;
(2008)
ehn480v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dobrzycki, P. Kralisz, K. Nowak, P. Prokopczuk, W. Kochman, J. Korecki, B. Poniatowski, J. Zuk, E. Sitniewska, H. Bachorzewska-Gajewska, et al.
Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals
Eur. Heart J.,
October 2, 2007;
28(20):
2438 - 2448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Maioli, F. Bellandi, M. Leoncini, A. Toso, and R. P. Dabizzi
Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial)
J. Am. Coll. Cardiol.,
April 10, 2007;
49(14):
1517 - 1524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gyongyosi, H. Domanovits, W. Benzer, M. Haugk, B. Heinisch, G. Sodeck, R. Hodl, G. Gaul, G. Bonner, J. Wojta, et al.
Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study
Eur. Heart J.,
December 1, 2004;
25(23):
2125 - 2133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Montalescot, M. Borentain, L. Payot, J. P. Collet, and D. Thomas
Early vs Late Administration of Glycoprotein IIb/IIIa Inhibitors in Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis
JAMA,
July 21, 2004;
292(3):
362 - 366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W.J van't Hof, N. Ernst, M.-J. de Boer, R. de Winter, E. Boersma, T. Bunt, S. Petronio, A.T Marcel Gosselink, W. Jap, F. Hollak, et al.
Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial
Eur. Heart J.,
May 2, 2004;
25(10):
837 - 846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. De Luca, N. Ernst, F. Zijlstra, A. W. J. van't Hof, J. C. A. Hoorntje, J.-H. E. Dambrink, A. T. M. Gosslink, M.-J. de Boer, and H. Suryapranata
Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty
J. Am. Coll. Cardiol.,
April 21, 2004;
43(8):
1363 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Eisenberg and S. Jamal
Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction
J. Am. Coll. Cardiol.,
July 2, 2003;
42(1):
1 - 6.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A Crouch, J. M Nappi, and K. I Cheang
Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome
Ann. Pharmacother.,
June 1, 2003;
37(6):
860 - 875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Lee, N. A. Herity, B. L. Hiatt, W. F. Fearon, M. Rezaee, A. J. Carter, M. Huston, D. Schreiber, P. M. DiBattiste, and A. C. Yeung
Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial
Circulation,
March 25, 2003;
107(11):
1497 - 1501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Moliterno and A. W. Chan
Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET
J. Am. Coll. Cardiol.,
February 19, 2003;
41(4_Suppl_S):
49S - 54S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zijlstra, N. Ernst, M.-J. de Boer, E. Nibbering, H. Suryapranata, J. C. A. Hoorntje, J.-H. E. Dambrink, A. W. J. van't Hof, and F. W. A. Verheugt
Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute st elevation myocardial infarction
J. Am. Coll. Cardiol.,
June 5, 2002;
39(11):
1733 - 1737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G MANOHARAN and A A J ADGEY
Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond
Heart,
September 1, 2001;
86(3):
259 - 261.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bogousslavsky and J. R. Leclerc
Platelet glycoprotein IIb/IIIa antagonists for acute ischemic stroke
Neurology,
September 1, 2001;
57(90002):
S53 - 57.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H Suryapranata, J P Ottervanger, E Nibbering, A W J van't Hof, J C A Hoorntje, M J de Boer, M J Al, and F Zijlstra
Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction
Heart,
June 1, 2001;
85(6):
667 - 671.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Zijlstra
CORONARY DISEASE: Acute myocardial infarction: primary angioplasty
Heart,
June 1, 2001;
85(6):
705 - 709.
[Full Text]
|
|
|
|
|
|
|
J. P. Collet, G. Montalescot, C. Lesty, Z. Mishal, J. Soria, R. Choussat, G. Drobinski, C. Soria, P. Pinton, P. Barragan, et al.
Effects of Abciximab on the Architecture of Platelet-Rich Clots in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Intervention
Circulation,
May 15, 2001;
103(19):
2328 - 2331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Le May, M. Labinaz, R. F. Davies, J.-F. Marquis, L. A. Laramee, E. R. O'Brien, W. L. Williams, R. S. Beanlands, G. Nichol, and L. A. Higginson
Stenting versus thrombolysis in acute myocardial infarction trial (STAT)
J. Am. Coll. Cardiol.,
March 15, 2001;
37(4):
985 - 991.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.D. Kovac and A.H. Gershlick
How should we detect and manage failed thrombolysis?
Eur. Heart J.,
March 2, 2001;
22(6):
450 - 457.
[PDF]
|
|
|
|
|
|
|
J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger
Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention
Chest,
January 1, 2001;
119(1_suppl):
321S - 336S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zahn, R. Schiele, S. Schneider, A. K. Gitt, H. Wienbergen, K. Seidl, C. Bossaller, H. J. Buttner, M. Gottwik, E. Altmann, et al.
Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis: Results from the pooled data of the maximal individual therapy in acute myocardial infarction (MITRA) registry and the myocardial infarction registry (MIR)
J. Am. Coll. Cardiol.,
December 1, 2000;
36(7):
2064 - 2071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zijlstra
Long-term benefit of primary angioplasty compared to thrombolytic therapy for acute myocardial infarction
Eur. Heart J.,
September 2, 2000;
21(18):
1487 - 1489.
[PDF]
|
|
|
|
|
|
|
C. P. Cannon, C. M. Gibson, C. T. Lambrew, D. A. Shoultz, D. Levy, W. J. French, J. M. Gore, W. D. Weaver, W. J. Rogers, and A. J. Tiefenbrunn
Relationship of Symptom-Onset-to-Balloon Time and Door-to-Balloon Time With Mortality in Patients Undergoing Angioplasty for Acute Myocardial Infarction
JAMA,
June 14, 2000;
283(22):
2941 - 2947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. i. I. S. Investigators
Abciximab in Acute Ischemic Stroke : A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study
Stroke,
March 1, 2000;
31(3):
601 - 609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Keeley and W. D. Weaver
Combination therapy for acute myocardial infarction
J. Am. Coll. Cardiol.,
December 1, 1999;
34(7):
1963 - 1965.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Abciximab Improves Early Infarct Artery Patency
Journal Watch Cardiology,
July 16, 1999;
1999(716):
3 - 3.
[Full Text]
|
|
|
|
